In a phase 2 study, Trans-Tasman Radiation Oncology Group (TROG) FASTRACK II, 70 older adults diagnosed with kidney cancer were treated with stereotactic ablative body radiotherapy (SABR). None of the patients experienced a local progression of their kidney cancer during the trial lifetime (median follow-up = 43 months), nor did any patients die from cancer. Overall survival was 99% 1 year following SBRT and 82% at 3 years. Side effects were minimal, with kidney function showing a slight decrease that stabilized after 2 years. Researchers concluded that there’s potential to compare SABR with surgical approaches in future trials, suggesting that many patients would prefer the noninvasive radiation method.
Reference: The ASCO Post Staff. Stereotactic Radiotherapy for Patients With Primary RCC Unsuitable for Surgery: FASTRACK II. The ASCO Post. Updated October 3, 2023. Accessed October 16, 2023. https://ascopost.com/news/october-2023/stereotactic-radiotherapy-for-patients-with-primary-rcc-unsuitable-for-surgery-fastrack-ii/
